Pathology and Lab Review Before Treatment in China

Prepare pathology slides, reports, biomarkers and laboratory trends for review before treatment in China, while protecting tissue and avoiding false comparisons.

Key takeaways

A pathology review is a fresh specialist interpretation of the source material. Translating the old report helps, but translation by itself does not amount to a pathology second opinion.
Send the final report, every addendum, specimen and block identifiers, representative slides or digital images, and the clinical question. When the report travels without the underlying specimen, there is a limit to what any reviewer can confirm.
Biomarker results must be tied to the tested specimen, method, date and disease context. A “negative” result can say as much about specimen quality or assay limits as about the biology itself.[1]
Laboratory trends need collection dates, units, reference ranges and the timing of treatment, transfusion or other interventions. Methods and ranges can differ from one laboratory to the next.[2]
Whether review may safely delay treatment, and which safety tests must be repeated after arrival, are decisions for the treating team. Couriers and coordinators do not make them.

Full guide

Treatment can hinge on a single line in a report: the tumour type, margin status, receptor expression, a molecular alteration, renal function or a clotting result. So before treatment starts, someone has to confirm that the result about to drive the decision is the right result — from the right patient and the right specimen, obtained by a suitable method at a clinically relevant time. Nobody is asking you to repeat every test.

That takes two separate reviews. A pathologist examines tissue or cells and interprets the disease. The treating team and laboratory specialists then judge whether blood, urine or other laboratory results are recent and comparable enough to carry the planned therapy.

Start With the Decision the Result Must Support

Ask the receiving team to finish this sentence: “Before we can recommend or begin treatment, we need to confirm…”

Possible answers include:

Whether the lesion is malignant and what type it is
Grade, stage-related features or surgical margins
Whether the submitted specimen is adequate for a required biomarker
Whether a reported biomarker matches a particular treatment context
Whether blood counts, kidney, liver or coagulation status permit treatment now
Whether an abnormal laboratory result is persistent, treatment-related or technically suspect

That sentence keeps the review at the right scale. Re-running every old test can waste tissue, money and time. Skipping the question the treatment actually depends on is just as wasteful.

What Belongs in a Pathology Review Packet

All report versions

Include the original-language preliminary report, the final report and every addendum or amendment. File them separately and label each one’s status. The newest page does not always replace what came before. An addendum often just adds to the main diagnosis.

Specimen identity

Record the patient name and identifier used by the original laboratory, the accession or pathology number, collection date, specimen site and side, procedure type and reporting institution. The National Health Commission’s pathology guidance requires reports to include identifiers, specimen site, pathology number, diagnosis, reporting physician and time.[3]

Material available for review

Ask the reviewing laboratory exactly what it accepts:

Stained glass slides
Unstained slides
Paraffin block or curls
Cytology slides or cell block
Flow-cytometry data
Digital whole-slide images
Molecular raw data or variant files, where useful

If you hold the only block, keep it until the release, tracking, return and tissue-use terms are clear. Chinese guidance requires medical institutions to maintain systems for borrowing and consultation involving slides and smears.[3]

Clinical context

Provide a concise history, the imaging site, prior therapy, the operative note and the question being asked. No pathologist should have to guess whether “lung lesion” means a primary lung tumour or possible metastasis from a prior cancer.

Report Translation Versus Pathology Re-Review

A translated report tells the Chinese team what the original pathologist wrote. A re-review puts the available slides, images or material in front of a second pathologist, who then issues their own interpretation.

Both can be useful, but they answer different questions.

For a re-review, ask whether the output will be:

A confirmation of the submitted diagnosis
A revised diagnosis
A descriptive consultation with unresolved differential diagnoses
A recommendation for additional stains, molecular testing or a new biopsy

NCI explains that a pathology second opinion may require slides and/or a paraffin block, and that patients should contact the reviewing institution about availability, costs and shipping requirements before sending material.[4]

When Two Pathologists Disagree

Two reports that disagree do not by themselves prove negligence. New slides, additional immunostains, an evolving classification, specimen limitations or genuine interpretive uncertainty can all produce a different reading.

Ask the Chinese reviewer to identify:

The exact point of disagreement
Which slide, stain or criterion drives it
Whether the difference changes treatment
Whether another subspecialty review or test could resolve it
Which report should be treated as current and how the original institution will be notified

Keep both reports on file. Never edit the first PDF to match the second — the treatment team needs the diagnostic history, uncertainty included.

Protect Limited Tissue

A small biopsy can be exhausted by repeated stains and broad sequencing. Before releasing a block or ordering more tests, ask:

How much tumour is present?
Which tests are essential for the next decision?
Can existing slides or prior data answer the question?
How many unstained sections are requested and at what thickness?
Will the block be returned, and what material is expected to remain?
Is a new biopsy clinically safer or more informative than consuming the old sample?

Choosing what runs first is a clinical prioritisation call. Ordering every available panel can burn through the tissue without making the care any better.

Read Biomarker Reports in Context

Biomarker testing looks at genes, proteins or other features to help select treatment. It does not help every patient, and each result is a snapshot of one sample at one time.[1]

For each result, identify:

Disease and treatment setting for which it is being considered
Specimen type, site and collection date
Tumour-cell content or other adequacy statement
Method, platform and genes or markers covered
Detected alteration and how it is reported
Limit of detection and assay limitations
Quality-control or failure comments
Whether the result is pathogenic, likely pathogenic, uncertain or otherwise classified
Which clinician or molecular team interprets treatment relevance

A variant of uncertain significance should not be treated as a drug target on its own. And when a report says “no alteration detected,” read the fine print first: a narrow panel, low tumour content or an old specimen can all hide a relevant alteration. NCI notes that tissue can be insufficient, tests can find no actionable marker, and tumour biomarkers can change over time.[1]

Keep tumour (somatic) testing apart from inherited (germline) testing. A possible inherited finding usually needs confirmation in a suitable normal sample, plus genetics counselling. Relatives should not hear “confirmed hereditary diagnosis” on the strength of tumour-only testing.

Build Laboratory Trends Without Inventing Comparability

For each treatment-relevant laboratory result, preserve:

Collection date and time
Test name
Numeric or qualitative result
Unit
The reporting laboratory’s reference range
Specimen type
Fasting or timing condition when relevant
Relationship to treatment, transfusion, dialysis, growth factor, steroids or another intervention

Methods and reference ranges vary between laboratories. MedlinePlus cautions that a value outside a range may not by itself indicate disease, a value inside the range does not guarantee health, and results from different laboratories may not be directly comparable.[2]

A trend chart is good for orientation, but every source report stays in the file. If units get converted, show the original value alongside the verified converted one. And never paste a number into a table without its unit.

Old Results May Be True but No Longer Current

A creatinine from six weeks ago described that day accurately, yet it can still be too old to clear today’s contrast study. A blood count drawn before chemotherapy cannot clear the next cycle. A coagulation test done before an anticoagulant adjustment may already be obsolete.

Ask the treating team which tests must be repeated in China and how close to treatment they must be collected. Common domains include blood counts, electrolytes, kidney and liver function, coagulation, pregnancy testing, infectious-disease screening, blood type and treatment-specific monitoring — the exact set depends on the patient and the intervention.

A test being foreign is not, on its own, a reason to repeat it. The legitimate triggers are the method, identity, specimen, recency or a treatment requirement.

Check for Identity and Specimen Mismatches

Before clinical interpretation, compare patient identifiers, accession numbers, collection sites and dates across:

Pathology requisition and report
Slide or block label
Operative or biopsy note
Imaging showing the sampled lesion
Molecular and immunohistochemistry addenda

If a left-sided lesion is paired with a right-sided specimen or the accession number differs, stop. The originating and reviewing laboratories need to reconcile the chain before any treatment relies on that result. A name-order difference introduced in translation may be purely administrative — document how it was resolved anyway.

Shipping Is Part of Specimen Integrity

Get written packing, temperature, courier, customs and address instructions from both laboratories. Ship with tracking and log every handoff. Slides break. Blocks soften in heat. Biological materials may require permits or special packaging.

The patient should know:

What was released and how many pieces
Who packaged it
Tracking number and recipient
Date received
What was consumed for testing
What will be returned and when

Do not ask an ordinary travel coordinator to improvise cross-border tissue shipment.

Decide Whether Treatment Waits

The reviewing pathologist can say what is still pending. Whether that pending information is likely to change treatment, and whether waiting is medically acceptable, is the treating clinician’s call.

Ask for three dates:

Expected receipt and adequacy check
Expected preliminary or final review
Latest clinically safe treatment decision point

With rapidly progressive disease or an urgent safety problem, the team may need to start an appropriate treatment before every optional test is finished. On the other hand, a travel schedule is never a reason to push ahead with an irreversible or high-risk treatment while an identity or diagnosis error is still unresolved.

The Pre-Treatment Review Note

Request a short integrated note stating:

Pathology diagnosis being used for treatment
Specimen and report reviewed
Material not available
Important discrepancy or uncertainty
Biomarkers confirmed and their limitations
Laboratory results accepted and those repeated locally
Remaining pending tests
Whether any pending item can change the plan
Named clinician responsible for the final treatment decision

With that note, a pile of reports becomes a decision that can be audited later.

Medical disclaimer: Pathology and laboratory interpretation is case-specific. This guide does not determine which review or repeat testing is clinically necessary. Treatment timing and specimen use must be decided by qualified professionals with access to the full case.

Related guides

How to Organise Medical Records Before Seeking Care in China
How to Share CT, MRI and Other Imaging Files With a Chinese Hospital
Getting a Cancer Second Opinion in China
How to Request English-Language Medical Records in China

FAQ

Is translating my pathology report enough?

For orientation, possibly. But translation is only translation. A second pathologist generally needs slides, a block or suitable digital material to independently assess the diagnosis.[4]

Must every patient repeat all laboratory tests in China?

No. The treating team should repeat a test when recency, method, identity, comparability or the treatment protocol calls for it. The original laboratory being abroad is not a reason by itself.

What if the biopsy block is very small?

Tell both teams before anything ships. Ask them to prioritise the tests, estimate how much tissue would remain, and weigh existing data or a new biopsy against exhausting the only block.

Does a negative molecular panel mean there is no target?

Not necessarily. Check the panel’s scope, the specimen’s adequacy, the detection limits and the timing. A negative result can be technically valid and still not answer the clinical question.[1]

Who decides whether treatment can start while results are pending?

That call sits with the treating clinician, who weighs — with input from pathology, the laboratory and the relevant specialty team — how likely the pending result is to change care against the risk of waiting.

Pathology and Laboratory Record Review Before Treatment in China